Common Sense: Based on the new task force guidanc
Post# of 72440
1) New Viruses
2) Drug combinations
The guidance talks to therapies in progress for COVID and to future threats. I can't imagine that B won't be tested against lot's of biological agents including more bacteria, fungus, viruses, etc.
Little Speculation:
I have a feeling there is a reason why the phase 2 hasn't started yet. Could there be a reason to wait for the new administration in office? Could they want to expand our trial (increasing n, or several different dosing arms or a combo arm)?.
My thoughts are: it seems silly and risky to just let IPIX do it own small trial without government/BP assistance and to only take action AFTER trial results. If good, I would think IPIX should already have stockpiled additional B and have a BP partner to help with increasing production, distribution, marketing etc.
Wonder what we are going to learn next?